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Introduction
Chronic hepatitis B is prevalent in Asia and Taiwan,
and a major cause of liver-related morbidity and mor-
tality.1 Hepatitis B virus (HBV) reactivation is a well-
recognized complication in HBV carriers undergoing
cancer chemotherapy.2 Patients with occult HBV infec-
tion, who are negative for hepatitis B surface antigen
(HBsAg), positive for antibody to hepatitis B core
antigen (anti-HBc) and positive for HBV DNA, also
carry the risk of HBV reactivation during chemotherapy,
especially in lymphoma patients.3 Current guidelines
for chronic hepatitis B suggest the use of prophylactic
antiviral therapy for HBsAg-positive patients at the onset
of chemotherapy.4 Rituximab, a chimeric monoclonal
antibody against the protein CD20, is the standard
treatment for CD20-positive non-Hodgkin’s lym-
phoma (NHL).5–7 HBV reactivation and progression
to fatal hepatic failure has been increasingly observed
in NHL patients with HBV infection (Table 1).8–19
The presence of antibody to hepatitis B surface antigen
(anti-HBs) has been identified to be a factor to prevent
HBV reactivation in patients with occult HBV infec-
tion receiving chemotherapy. In previous reports, most
of the patients were negative for anti-HBs.8 Here, we
report a case of reappearance of HBsAg and hepatitis B
e antigen (HBeAg) after 23 months of rituximab-based
immunochemotherapy in a HBsAg-negative and anti-
HBs-positive follicular lymphoma patient. Monitoring
liver function and early administration of antiviral agents
when reactivation of hepatitis B is recognized can suc-
cessfully prevent further progression of hepatitis B.
Case Report
A 72-year-old female patient was diagnosed with fol-
licular lymphoma, stage IV, by bone marrow biopsy
and computed tomography in January 2006. The
tumor involved the bone marrow, bilateral axillary,
supraclavicular, mediastinal, intra-abdominal and retro-
peritoneal lymph nodes, with initial presentation of a
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palpable solid mass in the neck. Virologic markers were
negative for HBsAg, and positive for anti-HBs before
chemotherapy.
Chemotherapy with R-OP (rituximab, vincristine,
prednisolone) was started on May 3, 2006, and was
completed on April 29, 2007, for a total of 9 cycles.
Then, a course of R-COP (rituximab, cyclophos-
phamide, vincristine, prednisolone) was administered
on August 15, 2007. Due to unsatisfactory response,
augmented chemotherapy regimen with R-CHOP
(rituximab, cyclophosphamide, pegylated liposomal
doxorubicin, vincristine, prednisolone) was started in
September 2007, and completed in January 2008, for a
total of 6 cycles. Another course of R-OP was admin-
istered on April 10, 2008.
Reduction in tumor size was documented on follow-
up computed tomography. Liver function tests had
been regularly monitored; there was no elevation of
serum aminotransferase levels throughout the courses
of chemotherapy. However, hepatitis flares with alanine
aminotransferase > 2 times the upper limit of normal
(119 U/L) was noted on April 22, 2008 (Figure 1).
Virologic markers were positive for HBsAg and
HBeAg, and there was disappearance of anti-HBs.
HBV DNA tests revealed a high HBV viral load
(1.71 × 109 copies/mL). Antiviral therapy with ente-
cavir 0.5mg daily was started immediately. Aminotrans-
ferase levels declined, and no hepatic decompensation
developed thereafter. HBV DNA tests at 1 month, 3
months and 12 months after antiviral therapy were
1.71 × 109, 9.71 × 106 and 2,880 copies/mL, respec-
tively. The patient is alive, and the tumor is in stable
disease status.
Discussion
Current AASLD (American Association for the Study
of Liver Diseases) and APASL (Asian Pacific Association
for the Study of the Liver) guidelines recommend rou-
tine HBsAg testing for patients at high risk for HBV
infection before the initiation of chemotherapy, and
prophylactic antiviral therapy should be administered
to hepatitis B carriers at the onset of chemotherapy and
maintained for 3–6 months afterwards.4,20 In contrast,
the incidence of HBV reactivation in patients with re-
solved infection who are HBsAg-negative, anti-HBs-
positive and anti-HBc-positive has been much lower,
and routine prophylactic antiviral treatment is not
mandatory. In recent years, the incorporation of ritux-
imab into the standard CHOP chemotherapy regimen
for CD20-positive NHL has been shown to improve
clinical outcomes.5 However, HBV reactivation in this
population has been increasingly reported. Yeo et al re-
ported that HBV reactivation developed in a high
proportion of lymphoma patients with occult HBV
infection undergoing rituximab-based chemotherapy.8
Among 21 diffuse large B cell lymphoma patients
who were HBsAg-negative and anti-HBc-positive, 
5 patients developed HBV reactivation after receiving
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Figure 1. Serum alanine aminotransferase (ALT) and total bilirubin (TB) levels during and after rituximab-based chemotherapy. Entecavir
(ETV) 0.5mg/day was initiated on day 806. R-OP= rituximab, vincristine, and prednisolone; R-COP= rituximab, cyclophosphamide, vincristine,
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R-CHOP chemotherapy, including 1 patient who died
of hepatic failure. These 5 patients with HBV reacti-
vation were all negative for anti-HBs. In contrast, none
of the patients who were HBsAg-negative and anti-
HBc-positive developed HBV reactivation after receiv-
ing CHOP alone. Male sex, absence of anti-HBs, and
use of rituximab were factors associated with HBV
reactivation. Therefore, the risk of HBV reactivation 
in patients with occult HBV infection could be strati-
fied according to the serologic profile of patients 
and the chemotherapy regimen. The risk is further
increased in the absence of anti-HBs during ritux-
imab-based chemotherapy.
Reactivation of HBV infection was studied in 626
Hong Kong patients with cancer who received cyto-
toxic chemotherapy over a 12-month period.21 Of these
patients with chronic HBV infection under chemother-
apy, HBV reactivation occurred in nearly 20%. Re-
activation was more likely to develop in patients who
were male, of younger age, HBeAg-negative, and diag-
nosed with lymphoma. A recent study from Singapore
showed an association between the presence of NHL
and HBV reactivation.22 The prevalence rate of HBV
infection in the study group was 10.3%, significantly
higher than the prevalence rate of 4.1% in the general
population. The high mortality rate of rituximab-
related HBV reactivation was reported in a recent
study.23 Among the patients with HBV reactivation
after rituximab treatment, 52% (13 of 25 patients) died
due to hepatic failure.
In our anti-HBs-positive case, due to the indolent
nature of follicular lymphoma, a total of 17 cycles of
rituximab-based chemotherapy was administered in
23 months (from May 2006 to April 2008), and HBV
reactivation eventually developed. The association of
duration of rituximab treatment and HBV reactivation
has not been well clarified. In previous reports of HBV
reactivation in HBsAg-negative, anti-HBc-positive lym-
phoma patients after rituximab treatment, the time of
HBV reactivation ranged from the 2nd to the 8th course
of anticancer therapy.8–19 Wu et al recently reported a
case of fatal HBV reactivation after R-CHOP chemo-
therapy.19 In their report, fatal HBV reactivation
developed after 6 cycles of R-CHOP chemotherapy
despite immediate administration of antiviral therapy.
In contrast, close monitoring of serum aminotransferase
levels, early recognition of HBV reactivation, and
prompt antiviral therapy in our patient resulted in
suppression of HBV DNA levels, normalization of
liver function, and avoidance of hepatic failure.
In HBsAg-positive lymphoma patients receiving
cytotoxic chemotherapy, clinical studies have shown
that prophylactic therapy with lamivudine could reduce
the risk of HBV reactivation, severity of hepatitis flares,
and mortality.2,24,25 Currently, there is no suggestion
for prophylactic antiviral therapy in HBsAg-negative,
anti-HBc-positive lymphoma patients undergoing che-
motherapy. However, there have been many cases to
date in which hepatic failure occurred despite admin-
istration of lamivudine after recognition of HBV reac-
tivation, presumably due to the relative delay in the start
of antiviral therapy.6 HBV reactivation is defined as an
increase in HBV DNA level of >1 log10 IU/mL.26
Therefore, we suggest screening HBV status, including
HBsAg, anti-HBs, and anti-HBc, for all patients before
they receive rituximab-based chemotherapy, and HBV
DNA should be tested if anti-HBc is positive. Because
HBV reactivation may develop within as few as 2 cycles
of chemotherapy, HBV DNA should be rechecked after
2 cycles of rituximab-based chemotherapy in anti-
HBc-positive patients, and antiviral treatment should
be started as soon as HBV DNA has increased 10-
fold compared to baseline, and > 2,000 IU/mL.
In conclusion, screening of HBV status for all
patients before they receive chemotherapy is important,
including HBsAg, anti-HBs, and anti-HBc. Regular
HBV DNA monitoring and prophylactic antiviral ther-
apy are highly recommended if there is evidence of
active or occult HBV infection.
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